ALX ONCOLOGY HOLDINGS INC 8-K

What Happened ALX Oncology Holdings Inc. announced on January 21, 2026 that its Board amended the 2025 Inducement Equity Incentive Plan to increase the number of common shares reserved for issuance. The Board added 1,300,000 shares, bringing the total reserved under the Inducement Plan to 2,800,000 shares. The Inducement Plan was originally approved by the Board in January 2025 and the increase was adopted without stockholder approval under Nasdaq’s inducement award rules.

Key Details

• Amendment effective January 21, 2026; filed on Form 8‑K.
• Added 1,300,000 shares; total reserved under the Inducement Plan = 2,800,000 shares.
• Awards available include nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units and performance shares.
• Under Nasdaq rules, inducement awards may be granted only to individuals who were not previously employees or non‑employee directors (or after a bona fide non‑employment period).
• The amended plan and form award agreements are attached as Exhibit 10.1 to the filing.

Why It Matters This amendment increases the pool of equity available to recruit and retain new executives and employees, which can be important for company growth and management building. If and when awarded and exercised/vested, these shares could dilute existing shareholders; however, the filing does not disclose any immediate awards or cash impact. Investors should monitor future equity-award disclosures (e.g., Form 4s, proxy statements) for details on actual grants and potential dilution.